Japan Industrial Partners
Meiji Yasuda Seimei Bldg. 14th Floor, 2-1-1 Marunouchi, Tokyo, Chiyoda-ku, 100-0005, Japan
Overview
Japan Industrial Partners, Inc. was founded in 2002, the business of business carve-out (spin-off) and independent medium-sized companies primarily due to the restructuring in large companies as an investment fund to support the activation of the business of Japanese companies of in the reconstruction, we have carried out the offer and management support of capital.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Financial Services
Investment portfolio
- BostonGene
Participated · Series B · Apr 2022
BostonGene provides AI-based molecular and immune profiling through its BostonGene Tumor Portrait™ Tests, which analyze tumor genomics, the tumor microenvironment, and host immunity to recommend therapies. Its integrated model combines genetics, transcriptomics, microenvironment, and tumor composition to give physicians a 360° overview of each tumor. Many academic and community oncologists across the United States have already adopted BostonGene’s Molecular Portrait Test to improve patient care. The company plans to use new capital to scale growth, continue innovation, expand clinical and research partnerships, and pursue international expansion. Leveraging NEC’s infrastructure, BostonGene and NEC intend to form a joint venture to bring solutions to patients in Japan and other Asian countries. The company is headquartered in Waltham, Mass. BostonGene develops a cloud-native biomedical software platform that combines genome and transcriptome sequencing, algorithms to estimate immune fitness and cancer characteristics, and a continuously updated expert-curated AI-driven database. The platform produces molecular profiles and delivers a patient-prioritized list of optimal immuno- and targeted therapy combinations based on tumor and tumor-microenvironment analysis. BostonGene emphasizes a holistic approach to defining optimal therapy combinations for individual patients, with particular focus on immuno- and targeted therapies. Founded in 2015, the company has evaluated its solution using extensive data in collaboration with leading U.S. cancer centers and maintains a robust intellectual property portfolio. The company recently secured financing to accelerate product development, collaborations, and team growth. Its stated mission is to enable physicians to provide each patient the highest probability of survival through personalized treatments.
Team
No current team members are available.